Even after Anvisa’s position, Bolsonaro insists on defending ‘early treatment’ – 01/18/2021



[ad_1]

Even after members of the National Health Surveillance Agency (Anvisa) refuted the existence of an early treatment against covid-19, the President of the Republic, Jair Bolsonaro, again today defended the preventive treatment of the disease. He also questioned the efficacy of Coronavac, a vaccine produced by the pharmaceutical company Sinovac and the Butantan Institute. The immunizing agent showed an overall efficacy of 50.38%

“I am not giving up on early treatment, I am not giving up. The vaccine is for those who have not yet received it. This vaccine is 50% effective, that is, if you throw a coin, it is 50% effective,” he said. the President of the Republic to supporters in the morning at the exit of the Palácio da Alvorada.

The video of the interaction was broadcast by the president’s son, Councilor Carlos Bolsonaro (Republicans-RJ), on the Telegram application. However, it is unclear whether the president says “I don’t give up” or whether supporters say “I don’t give up.”

The CEO also stressed that the side effects of Coronavac are still unknown because it is “somewhat experimental.”

Anvisa, however, in approving the vaccine’s emergency use on Sunday, said there is solid data on its safety and that the immunizer experienced no serious adverse reactions during its development.

“As far as I am concerned, the vaccine will not be mandatory. It is an emergency vaccine, 50% effective, something that still no one knows if we will have side effects or not,” Bolsonaro said.

As the newspaper O Estado de S. Paulo and Broadcast (Grupo Estado’s real-time news system) showed, in addition to highlighting the absence of therapeutic alternatives against covid-19, Anvisa’s servers and directors defended science on Sunday and vaccine safety.



[ad_2]